Monthly Archives: February 2010
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (JCO)
Purpose Pertuzumab is a humanized monoclonal antibody that inhibits human epidermal growth factor receptor 2 (HER2) heterodimerization and has single-agent activity in recurrent epithelial ovarian cancer. The primary objective of this phase II study was to characterize the safety and … Continue reading
Identification of Ovarian Cancer Symptoms in Health Insurance Claims Data
Abstract Background: Women with ovarian cancer have reported abdominal/pelvic pain, bloating, difficulty eating or feeling full quickly, and urinary frequency/urgency prior to diagnosis. We explored these findings in a general population using a dataset of insured women aged 40–64 and … Continue reading
Chemotherapy-induced Peripheral Neuropathy (NCI)
It usually starts in the hands and/or feet and creeps up the arms and legs. Sometimes it feels like a tingling or numbness. Other times, it’s more of a shooting and/or burning pain or sensitivity to temperature. It can include … Continue reading
Special Thanks to our Fabulous Chefs!
The Ovarian Cancer National Alliance thanks the fabulous chefs who supported us at our Annual Gala! On February 2, 2010, thirty seven of the best women chefs in and around the DC, Virginia and Maryland areas teamed up with the … Continue reading
Posted in Blog Leave a comment
Carboplatin—gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration (J. Onc. Pharmacy Practice)
Carboplatin—gemcitabine doublet is an important therapeutic option for patients with both previously treated and untreated ovarian cancer (OC). At the currently recommended dosing, its main toxicity is hematological, consisting of thrombocytopenia, neutropenia, including febrile neutropenia, and/or anemia. The use of … Continue reading
Toward Advocacy in Cancer Care for Older Adults: Survivors Have Cautious Personal Actions but Bold Advice for Others (J.AGS)
OBJECTIVES: To examine narratives of personal coping with the cancer experience and compare them with narratives of advice offered to other cancer patients by community-dwelling elderly cancer survivors. PARTICIPANTS: Interviews were conducted with 100 elderly adults who had reported cancer … Continue reading
Health Care Reform Update: White House Releases New Proposal
Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias? (Gynecol Oncol)
OBJECTIVE: To compare the survival impact of diagnosing recurrent disease by routine surveillance testing versus clinical symptomatology in patients with recurrent epithelial ovarian cancer (EOC) who have achieved a complete response following primary therapy. METHODS: We identified all patients who … Continue reading
Genome study shows what cancers have in common (Reuters)
Genetic abnormalities — missing DNA or duplicate DNA — that fuel the growth of one type of cancer may actually be at work in several others, U.S. researchers said on Wednesday. The finding, based on a large-scale study of the … Continue reading
Nonsteroidal Anti-Inflammatory Drugs and Risk for Ovarian and Endometrial Cancers in the Iowa Women’s Health Study
Background: Several epidemiologic studies have shown inverse associations between use of nonsteroidal anti-inflammatory drugs (NSAID) and incident ovarian cancer, but the results are inconsistent. There have been only a few studies examining possible links between NSAIDs and endometrial cancer risk. … Continue reading
The Ovarian Cancer Alliance of Ohio – Making Big Strides
The newly incorporated and independent Ovarian Cancer Alliance of Ohio has been busy this past year. The organization worked hard to educate the women of Ohio about the signs and symptoms of ovarian cancer. Last June, the Ovarian Cancer Alliance … Continue reading
Posted in Blog Leave a comment
FDA Announces new safety plan for anemia drugs
Washington, D.C – February 16, 2010 The Food and Drug Administration (FDA) released the final Risk Evaluation and Mitigation Strategy (REMS) for Erythropoetin Stimulating Agents (ESAs) marketed under the brand names Epogen, Procrit and Aranesp. The plan has been finalized … Continue reading
